Invitrogen

Theragent Welcomes Seasoned Cell Therapy Professional Brian Newsom as New Vice President of Business Development

Retrieved on: 
Tuesday, October 24, 2023
Therapy, Business development, MD, CDMO, Invitrogen, Doctor of Philosophy, MBA, Texas Tech University, Baylor College of Medicine, Growth, Texas A&M University, Marketing, Business, Microbiology, Thermo Fisher Scientific, Life Technologies, Patient, Management

ARCADIA, Calif., Oct. 24, 2023 /PRNewswire/ -- Theragent, a comprehensive cell & gene therapy CDMO focused on advancing next-generation cancer and rare disease treatments, announced that Brian Newsom will be joining the team as their new Vice President of Business Development effective October 16th, 2023.

Key Points: 
  • ARCADIA, Calif., Oct. 24, 2023 /PRNewswire/ -- Theragent, a comprehensive cell & gene therapy CDMO focused on advancing next-generation cancer and rare disease treatments, announced that Brian Newsom will be joining the team as their new Vice President of Business Development effective October 16th, 2023.
  • Mr. Newsom will join Theragent from his latest role as Senior Director of Business Development at KBI Biopharma.
  • Mr. Newsom brings with him a three-decade mix of both technical and business development experience within the cell therapy industry.
  • "Brian's technical knowledge, business development background and CDMO experience will help drive our continued growth as we expand our presence in the cell and gene therapy market.

Sapreme Appoints Experienced Industry Executives, Dr. Jeanne Bolger and Dr. Andre Hoekema, to its Board of Directors

Retrieved on: 
Thursday, July 20, 2023
Health, Biotechnology, Business development, Quality of life (healthcare), Therapy, MB, Invitrogen, Business, University College Dublin, Immunology, RNA, Antibody, Doctor of Philosophy, MD, Janssen Vaccines, Drug discovery, Knowledge, Neurology, Leiden University, Pharmaceutical industry, Management, Galápagos Islands, Medicine

Sapreme , a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.

Key Points: 
  • Sapreme , a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced the appointment of experienced biopharmaceutical industry executives Jeanne Bolger, MD, and Andre Hoekema, PhD, to its Board of Directors.
  • “We value the breadth and depth of Andre’s and Jeanne’s expertise and track record as Sapreme continues to grow and deliver on the potential of our technology.
  • She currently sits on the board of Life Healthcare SA and is Chairperson of the board at ExeVir and at Astrivax.
  • Dr. Hoekema currently serves as board member of biotech companies Artax Biopharma, Fibrocor Therapeutics and Mimetas B.V.

Thermo Fisher Scientific Reports First Quarter 2023 Results

Retrieved on: 
Wednesday, April 26, 2023
Science, Other Science, Research, San Francisco, Partnership, Food, University, Applied Biosystems, Drink, Table, University of California, San Francisco, COVID-19, TMO, GAAP, Thermo Fisher Scientific, Binding site, COVID-19 testing, Element, Acquisition, Soil, UCSF, CGMP, Water, Invitrogen, EPS, PPI, Mindful Scientific Inc., NYSE, PCR, Management, Video game, Pharmaceutical industry

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.

Key Points: 
  • Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 1, 2023.
  • GAAP operating income for the first quarter of 2023 was $1.56 billion, compared with $2.82 billion in the year-ago quarter.
  • Adjusted operating income for the first quarter of 2023 was $2.33 billion, compared with $3.45 billion in the year-ago quarter.
  • Thermo Fisher Scientific will hold its earnings conference call today, April 26, 2023, at 8:30 a.m. Eastern Time.

PhenomeX Appoints Peter Silvester to PhenomeX Board of Directors

Retrieved on: 
Monday, April 10, 2023
Human resources, Applied Biosystems, Audit, Compensation, Peter Silvester, Peter's Food Services, Life Technologies, Thermo Fisher Scientific, Science, Retirement, Acquisition, CELL, Invitrogen, Biology, Knowledge, Laboratory, Management

EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.

Key Points: 
  • EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- PhenomeX (Nasdaq: CELL), the functional cell biology company, today announced that Peter Silvester has been named to the PhenomeX board of directors, effective immediately.
  • Mr. Silvester most recently served as senior vice president and president of Life Sciences Solutions for Thermo Fisher Scientific and brings more than 25 years of experience in the life sciences tools industry as an executive and board member.
  • "I'm honored to join the PhenomeX board of directors at such a dynamic time for the company, and grateful to continue to serve scientists and influence science around the world," said Peter Silvester.
  • Mr. Silvester will serve on the Audit and Compensation & Leadership Development Committees of the board of directors.

Mark Stevenson Joins General Atlantic as Senior Advisor Focused on Life Sciences

Retrieved on: 
Friday, March 24, 2023
Asset Management, Professional Services, Finance, Applied Biosystems, Ingersoll Rand, University, Invitrogen, Biotechnology, Senior advisor, TMO, Personalized medicine, Life Technologies, MBA, Thermo Fisher Scientific, Genomics, NYSE, Acquisition, MD, General Atlantic, Management, Chemistry

General Atlantic, a leading global growth equity firm, announced today that Mark Stevenson has joined the firm as a Senior Advisor.

Key Points: 
  • General Atlantic, a leading global growth equity firm, announced today that Mark Stevenson has joined the firm as a Senior Advisor.
  • In his role, Mr. Stevenson will provide strategic counsel and support to the firm’s investment teams and portfolio companies in the Life Sciences sector.
  • General Atlantic formally established Life Sciences as a core sector in 2020.
  • As of December 31, 2022, General Atlantic has invested more than $2.5 billion in over 25 companies in the Life Sciences sector globally.

Artax Biopharma Appoints Andre Hoekema, Ph.D., to Company's Board of Directors

Retrieved on: 
Tuesday, March 7, 2023
Cytokine, Invitrogen, Genentech, Research, Business development, Autoimmune disease, Janssen Vaccines, Autoimmunity, Therapy, Leiden University, Patient, Mergers and acquisitions, Compugen (company), Intellectual property, Collaboration, Immunosuppression, Pharmaceutical industry, Medical device, Management

CAMBRIDGE, Mass., March 7, 2023 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company has appointed Andre Hoekema, Ph.D., to the Company's Board of Directors.

Key Points: 
  • CAMBRIDGE, Mass., March 7, 2023 /PRNewswire/ -- Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company has appointed Andre Hoekema, Ph.D., to the Company's Board of Directors.
  • Dr. Hoekema joins the Artax Biopharma Board of Directors as the Company is evaluating AX-158 in clinical trials.
  • Dr. Hoekema joins the Artax Biopharma Board of Directors as the Company is currently evaluating AX-158 in clinical trials.
  • He also serves as a supervisory board member of early-stage biotech companies Fibrocor Therapeutics, located in Canada, and Mimetas B.V. and Sapreme Technologies B.V., both headquartered in Holland.

Mercy BioAnalytics Announces Executive Leadership Changes

Retrieved on: 
Wednesday, February 15, 2023
Oncology, Health, General Health, Clinical Trials, Research, Science, Biotechnology, MBA, DNA, Insurance, Woman, TMO, Yale University, Neoplasm, Thermo Fisher Scientific, NYSE, Harvard Business School, LP, University, Citibank, Cell, Invitrogen, Partnership, Cell Signaling Technology, Life Technologies, Cancer, Doctor of Philosophy, Donaldson, Lufkin & Jenrette, Management, Mercy

“We founded Mercy to solve the inherent challenges in others’ use of scarce circulating tumor DNA (ctDNA), which has not been able to reliably detect cancer at its earliest stages,” said Blavin.

Key Points: 
  • “We founded Mercy to solve the inherent challenges in others’ use of scarce circulating tumor DNA (ctDNA), which has not been able to reliably detect cancer at its earliest stages,” said Blavin.
  • “At the same time, we created a unique culture that emphasizes humility, collaboration and a sense of urgency to create better tools with a transformational approach.
  • Mr. Blavin is co-founder of Mercy BioAnalytics and served as its CEO from March 2020 through February 2023.
  • He earned an MBA from Harvard Business School and holds a bachelor’s degree in accounting from the University of Michigan.

Thermo Fisher Scientific’s Advanced Analytical Instruments Receive R&D 100 Awards

Retrieved on: 
Thursday, December 15, 2022
Manufacturing, Other Manufacturing, Science, Other Science, Machinery, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Peptide, PPD, Food, R, Mindful Scientific Inc., MAM, Drug discovery, Patient, Science, Mass spectrometry, Patheon, Research, Chromatography, West Pharmaceutical Services explosion, Applied Biosystems, Multimedia, Plasma protein binding, Health, Fine chemical, Renewable energy

Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.

Key Points: 
  • Thermo Fisher Scientific Inc., the world leader in serving science, received R&D 100 Awards from R&D World Magazine for two of its most recently launched analytical instruments.
  • The R&D 100 Awards competition honors the latest innovations in science and technology, identifying the top 100 revolutionary technologies of the past year.
  • The Thermo Scientific Orbitrap Exploris MX Mass Detector was also a recipient of an R&D 100 Award in the Analytical/Test category .
  • Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

FDA Grants Emergency Use Authorization for Thermo Fisher Scientific’s Monkeypox Test

Retrieved on: 
Wednesday, December 14, 2022
Science, Other Science, Biotechnology, Pharmaceutical, Medical Supplies, Health, FDA, Infectious Diseases, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Severe acute respiratory syndrome coronavirus 2, PPD, Food, Mindful Scientific Inc., Monkeypox, Regulation of tobacco by the U.S. Food and Drug Administration, Infection, Patient, DNA, Science, Patheon, Research, PCR, Pharmaceutical Services Negotiating Committee, Polymerase chain reaction, FDA, Monkeypox virus, Applied Biosystems, COVID-19, Genetic, EUA, Health, Vaccine, Orthopoxvirus

Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its Applied Biosystems TaqPath Monkeypox/Orthopox Virus DNA Kit, a polymerase chain reaction (PCR) test designed to detect non-variola Orthopoxviruses, including monkeypox virus, in approximately three-and-a-half hours.
  • Ensuring that all U.S. laboratories have access to monkeypox PCR testing is a critical part of the response to this public health emergency, said Manoj Gandhi, senior medical director for Genetic Testing Solutions, Thermo Fisher Scientific.
  • In early 2020, Thermo Fisher was among the first companies to distribute an emergency use authorized assay to identify active SARS-CoV-2 infections with the TaqPath COVID-19 Combo Kit .
  • For Emergency Use Authorization Only; Rx Only
    Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion.

FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma

Retrieved on: 
Wednesday, December 7, 2022
Research, FDA, Genetics, Health Technology, Biotechnology, Pharmaceutical, Health, Optical, Science, Oncology, Laboratory, Fisher Scientific, Thermo Fisher Scientific, Invitrogen, Survival, PPD, Mindful Scientific Inc., Immunotherapy, HLA, Protein, Patient, Science, Patheon, Research, Diversified Pharmaceutical Services, Disease, FDA, Classification, Applied Biosystems, Cell, The New England Journal of Medicine, Uveal melanoma, Eye, Health, SECORE, Vaccine, Medical imaging

The marketing authorization is the first of its kind, making the SeCore CDx HLA Sequencing System the only commercially available HLA typing companion diagnostic.

Key Points: 
  • The marketing authorization is the first of its kind, making the SeCore CDx HLA Sequencing System the only commercially available HLA typing companion diagnostic.
  • Cancer immunotherapies, including T cell receptor therapies, have been shown to prolong survival for patients with metastatic or unresectable tumors.
  • Because these proteins are expressed on nearly all nucleated cells in the body, high-resolution HLA typing is a critical step for patient identification.
  • KIMMTRAK, the first and only FDA-approved T cell receptor therapy for metastatic or unresectable uveal melanoma, is indicated for adults who are HLA-A*02:01 positive.